Compare BioNano Genomics Inc (BNGO) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Mongodb Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Mongodb Inc trades at $440 (market cap $35.32B). The key difference: Mongodb Inc is far larger — about 2585.7× BioNano Genomics Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MDB | |
|---|---|---|
Market Cap | $13.66M | $35.32B |
Sector | Health | Technology |
52-Week High | $4.92 | $440.25 |
52-Week Low | $1.06 | $204.37 |
Enterprise Value | $16.26M | $32.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
MongoDB (MDB) trades at $416.67, up 4.48% in the last session, with a bullish technical setup per moving averages and ADX. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and strong analyst sentiment, with 82% buy ratings, support optimism. The stock is near its pivot point of $412, with resistance at $428.
Outlook: MDB's growth trajectory and AI-driven demand present upside, but profitability concerns and high valuation multiples (P/S 13.73) pose risks. Investors should weigh revenue momentum against persistent losses and competitive pressures in the database software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
